NCT00198510

Brief Summary

The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
750

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Nov 1998

Typical duration for phase_3

Geographic Reach
3 countries

73 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1998

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2001

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2003

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 20, 2005

Completed
Last Updated

March 15, 2013

Status Verified

March 1, 2013

Enrollment Period

2.8 years

First QC Date

September 13, 2005

Last Update Submit

March 14, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Resolution of Vitreous Hemorrhage

    Laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula \& at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved

    3 months

Secondary Outcomes (2)

  • Incidence of complications & adverse events

    12 months

  • Visual Acuity

    3 months, 6 months, 12 months

Study Arms (2)

Vitrase

EXPERIMENTAL

A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.

Drug: Vitrase

Observation

NO INTERVENTION

Observation only, no medication or intravitreal injection

Interventions

7.5 IU of Vitrase

Also known as: ovine hyaluronidase
Vitrase

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present \>/= 1 month by history or exam
  • BCVA is worse than 20/200 at time of screening

You may not qualify if:

  • Corneal or lenticular abnormalities that preclude fundus observation
  • Ongoing ocular infection, inflammation or history of herpetic corneal lesion
  • Current or prior retinal detachment or retinal tears or breaks or intraocular tumor
  • More than 1 severe vitreous hemorrhage within 6 months
  • Previous vitrectomy for any reason
  • Hemorrhage is exclusively pre-retinal, or old \& organized
  • Prior Vitrase for intravitreal injection in either eye
  • No light perception in either eye at any time
  • Known contraindications to study medication
  • Sickle cell disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (73)

Retina Centers, PC

Tucson, Arizona, 85704, United States

Location

Retina Vitreous Associates Medical Group

Beverly Hills, California, 90211, United States

Location

Maria E. Castillejos, MD

Chula Vista, California, 91910, United States

Location

Natural Vision

Fresno, California, 93710, United States

Location

Eye Medical Center of Fresno

Fresno, California, 93721, United States

Location

Jerry Sebag, MD

Huntington Beach, California, 92647, United States

Location

University of California, Irvine

Irvine, California, 92697, United States

Location

California VitreRetinal Center

Menlo Park, California, 94025, United States

Location

Southern California Desert Retina Consultants

Palm Springs, California, 92262, United States

Location

Retinal Consultants

Sacramento, California, 95819, United States

Location

H. Richard McDonald, MD

San Francisco, California, 94109, United States

Location

Santa Clara Valley Medical Centre

San Jose, California, 95128, United States

Location

Robert L. Avery, MD

Santa Barbara, California, 93103, United States

Location

Olive View/UCLA Medical Center

Sylmar, California, 91342, United States

Location

Retina Consultants of Southern Colorado

Colorado Springs, Colorado, 80909, United States

Location

University of Colorado Health Sciences Center

Denver, Colorado, 80262, United States

Location

Danbury Eye Physicians & Surgeons

Danbury, Connecticut, 06810, United States

Location

New England Retina Associates

Hamden, Connecticut, 06518, United States

Location

Florida Eye Clinic

Altamonte Springs, Florida, 32701, United States

Location

Eye Centers of Florida

Fort Myers, Florida, 33901, United States

Location

Sarasota Retina Institute

Sarasota, Florida, 34239, United States

Location

Scott E. Pautler, MD

Tampa, Florida, 33614, United States

Location

Retina Center at Pali Momi

‘Aiea, Hawaii, 96701, United States

Location

Illinois Retina Associates SC

Chicago, Illinois, 60612, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

American Eye Institute

New Albany, Indiana, 47150, United States

Location

Felix N. Sabates Eye Associates

Prairie Village, Kansas, 66208, United States

Location

King Y. Lee, MD

Shawnee Mission, Kansas, 66202, United States

Location

Kurt A. Gitter, MD

New Orleans, Louisiana, 70115, United States

Location

Retina Specialists

Baltimore, Maryland, 21204, United States

Location

Wilmer Eye Institute/Johns Hopkins University School of Medicine

Baltimore, Maryland, 21287, United States

Location

Retina Consultants, PC

Bethesda, Maryland, 20817, United States

Location

Schepens Retina Associates

Boston, Massachusetts, 02215, United States

Location

VitreoRetinal Associates

Grand Rapids, Michigan, 49525, United States

Location

Retina Center PA

Minneapolis, Minnesota, 55404, United States

Location

Hunkeler Eye Centers

Kansas City, Missouri, 64111, United States

Location

Retina Associates of Kansas City

Kansas City, Missouri, 64151, United States

Location

The Center for Advanced Medicine/Barnes Retina Institute

St Louis, Missouri, 63110, United States

Location

Robert Wood Johnson Medical School/Retina Vitreous Center

New Brunswick, New Jersey, 08701, United States

Location

Retina Associates of New Jersey

Teaneck, New Jersey, 07666, United States

Location

Long Island Vitreo Retinal Consultants

Great Neck, New York, 11021, United States

Location

Ronni M. Lieberman, MD

New York, New York, 10021, United States

Location

Retina Vitreous Surgeons of Central NY

Syracuse, New York, 13224, United States

Location

Charlotte Eye, Ear, Nose & Throat Association

Charlotte, North Carolina, 28210, United States

Location

Carolina Eye Associates, PA

Raleigh, North Carolina, 27612, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Retina Associates of Cleveland

Cleveland, Ohio, 44195, United States

Location

Retina Consultants, Ohio State University

Columbus, Ohio, 43210, United States

Location

Dean A. McGee Eye Institute

Oklahoma City, Oklahoma, 73104, United States

Location

Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States

Location

Retina Research of Wills Eye Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Carim Eye & Retina Center

Wyomissing, Pennsylvania, 19606, United States

Location

Southeastern Retina Associates, PC

Knoxville, Tennessee, 37920, United States

Location

Retina-Vitreous Associates

Nashville, Tennessee, 37203, United States

Location

Retinal Vascular Center

Houston, Texas, 77002, United States

Location

Cullen Eye Institute/Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Valley Retina Institute, PA

McAllen, Texas, 78503, United States

Location

John Moran Eye Center

Salt Lake City, Utah, 84132, United States

Location

Vista Retinal Consultants

Roanoke, Virginia, 24016, United States

Location

Virginia Mason Medical Center

Seattle, Washington, 98101, United States

Location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Vancouver Eye Care Center/University of British Columbia

Vancouver, British Columbia, V5Z 3N9, Canada

Location

Dalhousie University

Halifax, Nova Scotia, B3H 2Y9, Canada

Location

Ivey Institute of Ophthalmology

London, Ontario, N6A 4G5, Canada

Location

University of Ottawa Eye Institute

Ottawa, Ontario, K1H 8L6, Canada

Location

Toronto Western Hospital

Toronto, Ontario, M2P 1E3, Canada

Location

Royal Victoria Hospital

Montreal, Quebec, H3A 1A1, Canada

Location

Centre Hospitalier de l'Universite Laval (CHUL)

Sainte-Foy, Quebec, G1V 4G2, Canada

Location

The Medical Centre Pasqua Hospital

Regina, Saskatchewan, S4T 1A5, Canada

Location

Saskatoon City Hospital

Saskatoon, Saskatchewan, S7K 0M7, Canada

Location

Instituto de Oftalmologia, Fundacion Conde de Valenciana

Col. Obrera, Mexico City, 06080, Mexico

Location

Association Para Evitar la Ceguera en Mexico

Coyacan, Mexico City, 04030, Mexico

Location

Fundacion Hospital, Nuestra Senora de la Luz IAP

Cuahtemoc, Mexico City, 06030, Mexico

Location

Related Publications (1)

  • Bhavsar AR, Grillone LR, McNamara TR, Gow JA, Hochberg AM, Pearson RK; Vitrase for Vitreous Hemorrhage Study Groups. Predicting response of vitreous hemorrhage after intravitreous injection of highly purified ovine hyaluronidase (Vitrase) in patients with diabetes. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4219-25. doi: 10.1167/iovs.07-1602. Epub 2008 Apr 25.

MeSH Terms

Conditions

Vitreous HemorrhageDiabetic Retinopathy

Interventions

Chondroitinases and Chondroitin Lyases

Condition Hierarchy (Ancestors)

Eye HemorrhageEye DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsRetinal DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Intervention Hierarchy (Ancestors)

SulfatasesEsterasesHydrolasesEnzymesEnzymes and CoenzymesPolysaccharide-LyasesCarbon-Oxygen LyasesLyases

Study Officials

  • Lisa R Grillone, PhD

    ISTA Pharmaceuticals, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 20, 2005

Study Start

November 1, 1998

Primary Completion

September 1, 2001

Study Completion

March 1, 2003

Last Updated

March 15, 2013

Record last verified: 2013-03

Locations